Skip to main content
Top
Published in: Supportive Care in Cancer 1/2010

Open Access 01-01-2010 | Original Article

Evaluation and comparison of two prognostic scores and the physicians’ estimate of survival in terminally ill patients

Authors: S. Stiel, L. Bertram, S. Neuhaus, F. Nauck, C. Ostgathe, F. Elsner, L. Radbruch

Published in: Supportive Care in Cancer | Issue 1/2010

Login to get access

Abstract

Background

Most terminally ill patients request information about their remaining life span. Professionals are not generally willing to provide prognosis on survival, even though they are expected to be able to do so from their clinical experience. This study aims to find out whether the standardized instruments Palliative Prognostic Index (PPI) and the Palliative Prognostic Score (PaP-S) are appropriate, specific, and sensitive to estimate survival time in patients receiving inpatient palliative care in Germany.

Method

PPI and PaP-S were assessed in addition to the core documentation data set of the Hospice and Palliative Care Evaluation for patients admitted to the palliative care units in Aachen, Bonn, and Cologne. Time of survival was assessed with repeated phone calls to the family and was defined as the difference between the day of completion of the instruments (excluded) and the day of death (included).

Results

Survival time was compared with physicians’ estimations and prognostic scores in 83 patients. Whereas the estimates of the PPI and the PaP-S correlate highly, even higher correlations are found for the physicians’ prognosis and the scores. Correlations between survival time and the prognostic scores or physicians’ prognosis were lower. Physicians’ estimations overestimated survival time on average fourfold. Estimations were more often correct for very good and very bad prognosis.

Discussion

The prognostic scores are not able to produce a precise reliable prognosis for the individual patient. Nevertheless, they can be used for ethical decision making and team discussions. Estimating survival time from clinical experience seems to be easier for very bad or very good prognosis for physicians.
Literature
11.
go back to reference Lindena G, Nauck F, Bausewein C et al (2005) Quality assurance in palliative medicine—results of the core documentation of 1999–2002. Z Arztl Fortbild Qualitatssich 99:555–565PubMed Lindena G, Nauck F, Bausewein C et al (2005) Quality assurance in palliative medicine—results of the core documentation of 1999–2002. Z Arztl Fortbild Qualitatssich 99:555–565PubMed
13.
go back to reference Pirovano M, Maltoni M, Nanni O et al (1999) A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage 17:231–239. doi:10.1016/S0885-3924(98) 00145-6 CrossRefPubMed Pirovano M, Maltoni M, Nanni O et al (1999) A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage 17:231–239. doi:10.​1016/​S0885-3924(98) 00145-6 CrossRefPubMed
14.
go back to reference Anderson F, Downing GM, Hill J, Casorso L, Lerch N (1996) Palliative performance scale (PPS): a new tool. J Palliat Care 12:5–11PubMed Anderson F, Downing GM, Hill J, Casorso L, Lerch N (1996) Palliative performance scale (PPS): a new tool. J Palliat Care 12:5–11PubMed
Metadata
Title
Evaluation and comparison of two prognostic scores and the physicians’ estimate of survival in terminally ill patients
Authors
S. Stiel
L. Bertram
S. Neuhaus
F. Nauck
C. Ostgathe
F. Elsner
L. Radbruch
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 1/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0628-0

Other articles of this Issue 1/2010

Supportive Care in Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine